成年人的全身性巨细胞瘤:2023年关于诊断,风险分层和管理的更新
1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
American journal of hematology
|June 13, 2023
概括
系统性乳腺细胞瘤 (SM) 涉及异常的乳腺细胞生长. 诊断依赖于骨髓集群和特定标记物,其亚型从惰到高级形式,需要量身定制的治疗.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 系统性巨细胞症 (SM) 是一种罕见的疾病,其特征是皮外器官中巨细胞 (MC) 的克隆增殖.
- 诊断包括在骨髓或其他器官中识别多焦点的MC集群,以及诸如血清三酶升高和特定的MC标志物表达等小标准.
研究的目的:
- 概述系统性巨细胞瘤的诊断标准.
- 详细介绍SM亚型的风险分层和分类.
- 审查不同类型的SM的当前和新兴治疗策略.
主要方法:
- 诊断标准包括主要标准 (骨髓MC集群) 和次要标准 (血清三酶,MC免疫类型,KIT突变).
- 风险分层涉及将SM分类为惰性/燃烧 (ISM/SSM) 或高级形式 (侵略性SM,SM与关联的骨髓瘤瘤,巨细胞白血病) 并确定预后突变.
- 治疗方法根据SM亚型进行分类,重点是对ISM的症状控制和细胞减小疗法或针对高级SM的向药物.
主要成果:
- 确定SM的亚型对于指导治疗至关重要,沉着的形式是通过症状来管理的,而高级的形式需要细胞还原或向治疗.
- 铁氨酸激酶抑制剂,如中氨酸和阿瓦普里提尼布,在治疗多发性硬化症方面取得了重大进展.
- 在多个突变的关联髓瘤 (SM-AMN) 的MS中,阿瓦普里提尼布的疗效需要进一步调查.
结论:
- 准确的诊断和风险分层是有效的系统性巨细胞瘤管理的基础.
- 向疗法,特别是氨酸激酶抑制剂,已经改变了高级MS的治疗格局.
- 持续的研究对于优化治疗策略至关重要,特别是对于复杂的病例,如多变异的SM-AMN.
相关概念视频
01:20Asthma: Pathogenesis and Management
461
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
461
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:14Myocarditis III: Medical Management
9
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
9
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
01:26Mitral Stenosis III: Medical Management
14
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
14
01:24Cystic Fibrosis: Management
199
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
199